Family members without inherited mutation have increased risk of melanoma

December 8, 2017, Karolinska Institutet
Credit: Wikimedia Commons/National Cancer Institute

In families who carry certain inherited mutations that increase the risk for melanoma, members who do not carry the mutation also have an increased risk of melanoma, a study from Karolinska Institutet published in Genetics in Medicine reports. The phenomenon, which is called phenocopy, could result from other shared risk-enhancing genes or environmental factors within the families.

Malignant of the skin is one of the fastest increasing cancer types in the West. The main risk factors for melanoma are UV light exposure and hereditary factors. It is therefore relatively common for the afflicted to have family members with the disease. Inherited of the tumour suppressor gene CDKN2A are the strongest known risk factors for familial melanoma and mutations in this gene also increase the risk of other cancers. Children, siblings or parents of mutation carriers have a 50-50 chance of also having the mutation, which can be identified with a gene test.

The present study included Swedish and American families with inherited CDKN2A mutations. The researchers studied whether family members who have not inherited the mutation have any higher than normal risk of developing melanoma or other cancers.

Melanoma, but no other cancers, was more common in the non-carriers in these families compared to the normal population. The phenomenon whereby non-carriers of a specific mutation copy the phenotype (in this case melanoma) from their mutation-carrying relatives is known as phenocopy.

"Phenocopy can be caused by other risk-modifying or exposure patterns that increase the probability of the specific phenotype manifesting itself," says the study's first author Hildur Helgadottir, researcher at Karolinska Institutet's Department of Oncology-Pathology, Stockholm, Sweden.

Previous studies have shown that people with the mutation who also have certain pigmentation variants run an even higher risk of melanoma. Even though the CDKN2A mutation should be present in all populations, it has almost exclusively been identified in families with a Caucasian heritage.

"This suggests that dark-skinned people with this mutation probably don't develop melanoma as often and are therefore not tested for this specific mutation, presumably because they lack the risk-modifying pigmentation variants that increase the risk of melanoma," says Dr Helgadottir.

The researchers believe that such pigmentation variants also contribute to a higher melanoma risk in the family members who do not carry the mutation.

"Our results suggest that that test negatively for their family's CDKN2A mutation should be informed that they still can have an increased risk of developing melanoma. They should be advised to avoid sunburn, be aware of any change in their moles, and some might even need to be monitored by a dermatologist," says Dr Helgadottir.

Explore further: Inherited mutation doubles the risk of death from malignant melanoma

More information: Hildur Helgadottir et al. Phenocopies in melanoma-prone families with germ-line CDKN2A mutations, Genetics in Medicine (2017). DOI: 10.1038/GIM.2017.216

Related Stories

Inherited mutation doubles the risk of death from malignant melanoma

June 14, 2016
People with malignant melanoma with an inherited mutation in a certain gene are twice as likely to die of the disease, according to a new study carried out by researchers at Karolinska Institutet and Lund University in Sweden. ...

Why some moles become melanoma still a mystery

August 11, 2017
Testing for two gene mutations commonly associated with melanoma would be insufficient to determine whether a mole could turn cancerous, University of Queensland research has found.

Researchers identify key mutation that suppresses the immune system in melanoma

March 7, 2017
University of California, Irvine researchers have identified a specific mutation that allows melanoma tumor cells to remain undetected by the immune system. The finding may lead to the development of better immunotherapies ...

MITF p.E318K prevalence similar, regardless of CDKN2A

December 11, 2015
(HealthDay)—The prevalence of MITF p.E318K is similar in patients with melanoma, irrespective of the presence of CDKN2A mutations, according to a study published online Dec. 10 in JAMA Dermatology.

What are risk factors for melanoma in kidney transplant recipients?

July 26, 2017
Kidney transplant patients appear to be at a greater risk of developing melanoma than the general population and risk factors include being older, male and white, findings that corroborate results demonstrated in other studies, ...

Recommended for you

Dying cancer cells make remaining glioblastoma cells more aggressive and therapy-resistant

June 21, 2018
A surprising form of cell-to-cell communication in glioblastoma promotes global changes in recipient cells, including aggressiveness, motility, and resistance to radiation or chemotherapy.

Novel therapy makes oxidative stress deadly to cancer

June 21, 2018
Oxidative stress can help tumors thrive, but one way novel cancer treatments work is by pushing levels to the point where it instead helps them die, scientists report.

Existing treatment could be used for common 'untreatable' form of lung cancer

June 21, 2018
A cancer treatment already approved for use in certain types of cancer has been found to block cell growth in a common form of lung cancer for which there is currently no specific treatment available.

Researchers uncover new target to stop cancer growth

June 21, 2018
Researchers at the University of Wisconsin-Madison have discovered that a protein called Munc13-4 helps cancer cells secrete large numbers of exosomes—tiny, membrane-bound packages containing proteins and RNAs that stimulate ...

New therapeutic opportunity for the treatment of resistant malignant melanoma

June 21, 2018
A team of researchers led by Dr. Pierre Close, WELBIO researcher at the ULiège GIGA Institute and Dr. Francesca Rapino has uncovered a new therapeutic opportunity in the treatment of malignant melanoma that has acquired ...

New treatment helps avoid deafness in child chemotherapy patients

June 21, 2018
An international trial has found that a medicine commonly used to treat poisoning is effective in reducing deafness in children receiving chemotherapy for cancer.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.